Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria; and VAX-XL, a third-generation pneumococcal conjugate vaccine. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Frequently asked questions
What sector does Vaxcyte, Inc (PCVX) operate in?
Vaxcyte, Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Vaxcyte, Inc (PCVX) current stock price?
As of the latest data, Vaxcyte, Inc stock price is $60.89, with a previous close of $61.09. Vaxcyte, Inc lost -$0.20 in the last trading session, representing a -0.32% loss.
What is Vaxcyte, Inc (PCVX) current market capitalization?
Vaxcyte, Inc market cap is approximately 9.06 billion.
What is Vaxcyte, Inc (PCVX) Earnings Per Share (EPS)?
The trailing EPS is -$7.55, and the forward EPS is -$7.22.
What is Vaxcyte, Inc (PCVX) EBITDA?
Vaxcyte, Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -292.50 million.
Does Vaxcyte, Inc (PCVX) pay dividends?
No. Vaxcyte, Inc does not pay a dividend.
What is Vaxcyte, Inc (PCVX) beta (volatility) score?
Vaxcyte, Inc has a beta of 1.210, suggesting it is more volatile than the market.
